Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMTX 100

Next Previous
Drug Profile

AMTX 100

Alternative Names: AMTX-100; AMTX-100 CF3; AMTX-100-CF

Latest Information Update: 29 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vanderbilt University
  • Developer Amytrx Therapeutics
  • Class Anti-inflammatories; Peptides; Skin disorder therapies
  • Mechanism of Action Transcription factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Atopic dermatitis
  • Phase I Acne; Cutaneous lupus erythematosus; Herpes zoster; Psoriasis; Rosacea
  • Preclinical Age-related macular degeneration; Asthma; Atherosclerosis; Autoimmune disorders; Conjunctivitis; COVID 2019 infections; Crohn's disease; Diabetic retinopathy; Eosinophilic oesophagitis; Herpes simplex virus type 1 infections; Herpes simplex virus type 2 infections; Hypercholesterolaemia; Inflammatory bowel diseases; Nasal polyps; Non-alcoholic steatohepatitis; Rheumatoid arthritis; Sinusitis; Sjogren's syndrome; Type 1 diabetes mellitus; Uveitis
  • Research Cancer

Most Recent Events

  • 29 Oct 2025 AMTX 100 is still in Preclinical trials in Eosinophilic oesophagitis in USA (PO, Parenteral) (Amytrx Therapeutics pipeline; October 2025)
  • 02 Jan 2024 Amytrx Therapeutics completes a phase I/II trial in Atopic dermatitis in the US (Topical, Cream) (NCT04313400)
  • 25 Jul 2023 Interim adverse events and efficacy data from a phase-I/II trial in Atopic dermatitis released by Amytrx Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top